SAM
PLX icon

Silverback Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Silverback Asset Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-27,220
Closed -$1.23M – 63
2013
Q3 		$1.23M Buy
+27,220
New +$1.4M 0.1% 58

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Silverback Asset Management's PLX Position: Q4 2013 in Review

Silverback Asset Management sold out of Protalix BioTherapeutics (PLX) in Q4 2013, closing a stake of 27,220 shares — an estimated $1.23M sold.

Silverback Asset Management first reported a position in PLX in Q3 2013 and held it in 1 quarter. The position peaked at $1.23M in Q3 2013. 45 funds tracked by Wall St. Rank hold PLX as of Q4 2013.

  • Silverback Asset Management reported no remaining Protalix BioTherapeutics position as of Q4 2013 after selling out during the quarter.
  • Silverback Asset Management sold 27,220 Protalix BioTherapeutics shares in Q4 2013, an estimated $1.23M.
  • Silverback Asset Management first reported a position in Protalix BioTherapeutics in Q3 2013 and held it in 1 quarter.
  • Silverback Asset Management's Protalix BioTherapeutics position peaked at $1.23M in Q3 2013.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2013.

Based on Silverback Asset Management's 13F filing for Q4 2013, filed 14 Feb 2014.